Vancomycin for Staphylococcus aureus therapy of respiratory tract infections: the end of an era?
Nathwani
Dilip
D
Infection and Immunodeficiency Unit (Ward 42), East Block, Ninewells Hospital (Tayside University Hospitals), DD1 9SY, Dundee, UK. dilip.nathwani@tuht.scot.nhs.uk
Tillotson
Glenn S
GS
D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008712:Methicillin / Q000494:pharmacology; D016106:Methicillin Resistance; D010406:Penicillins / Q000494:pharmacology; D011023:Pneumonia, Staphylococcal / Q000188:drug therapy* / Q000382:microbiology; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification; D014640:Vancomycin / Q000494:pharmacology / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D010406:Penicillins; D014640:Vancomycin; D008712:Methicillin